Cosmos Health Projects $12M Revenue, Eyes $11.5M Acquisition

Edgen Stock·Mar 19 2026, 17:06

Share to

Share to

Copy link

Key Takeaways

Cosmos Health issued a bullish corporate update, detailing significant U.S. expansion, a new acquisition target, and initiatives to address its stock valuation. The company is signaling aggressive growth through both organic product sales and strategic M&A, supported by strong underlying financials and new analyst coverage.

U.S. Expansion: The company projects its NOOR product line will generate over $12 million in annualized revenue in the United States, supported by gross margins of approximately 75%.
Strategic Acquisition: Cosmos signed a Letter of Intent (LOI) to acquire a pharmacy distribution network valued at $11.5 million, expanding its operational footprint.
Valuation Focus: Management is evaluating the sale of over $18 million in non-core assets and highlighted new analyst coverage from Zacks setting a $4.50 per share valuation.

US Expansion Targets Over $12M in High-Margin Revenue

Cosmos Health (NASDAQ:COSM) is launching a significant expansion in the United States, projecting its NOOR Collagen product alone will generate more than $12 million in annualized revenue. The company's strategic push is underpinned by strong profitability metrics, with its Sky Premium Life products expected to achieve gross margins of approximately 75%. This move is part of a broader trend of record revenue and improving operating metrics, as stated in its March 19, 2026 corporate update. Management confirmed that recent geopolitical turmoil has had a negligible impact on its operations, allowing the company to maintain its strong growth trajectory.

Growth Strategy Bolstered by $11.5M Acquisition LOI

To accelerate its growth, Cosmos Health has signed a letter of intent to acquire a pharmacy distribution network valued at $11.5 million. This potential acquisition complements the company's organic growth and is part of a larger strategy to enhance shareholder value. Management is also evaluating the monetization of over $18 million in non-core real estate and digital assets. The proceeds could be used to fund further strategic investments or share repurchases. Underscoring this optimistic outlook, Zacks Small-Cap Research initiated coverage on the company with a valuation of $4.50 per share, signaling external confidence in the firm's strategic direction.